# Princess Alexandra Hospital

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/princess-alexandra-hospital/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 49 |
| Citations | 1,405,553 |
| City | Brisbane |
| Country | AU |
| Description | Princess Alexandra Hospital is a research organisation in Brisbane, AU. OpenAlex records 16,851 works and 1,405,553 citations for it. 3,069 researchers list it as their most recent affiliation. |
| Homepage | https://www.metrosouth.health.qld.gov.au/hospital-and-health-centres/princess-alexandra-hospital |
| OpenAlex ID | https://openalex.org/I2801814493 |
| Region | Queensland |
| Researchers | 3,069 |
| ROR ID | https://ror.org/04mqb0968 |
| Type | healthcare |
| Works | 16,851 |

## University papers

Showing 12 of 35.

- [Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer](https://scholariq.org/papers/crizotinib-versus-chemotherapy-in-advanced-i-alk-i-positive-lung-cancer/)
- [Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations](https://scholariq.org/papers/phase-iii-study-of-afatinib-or-cisplatin-plus-pemetrexed-in-patients-with/)
- [Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-lung-cancer-with-a-high-tumor-mutational-burden/)
- [Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-advanced-non-small-cell-lung-cancer/)
- [Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis](https://scholariq.org/papers/clinical-practice-guideline-the-diagnosis-management-and-prevention-of/)
- [Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials](https://scholariq.org/papers/afatinib-versus-cisplatin-based-chemotherapy-for-egfr-mutation-positive-lung/)
- [Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial](https://scholariq.org/papers/cetuximab-plus-chemotherapy-in-patients-with-advanced-non-small-cell-lung-cancer/)
- [Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study](https://scholariq.org/papers/combination-nivolumab-and-ipilimumab-or-nivolumab-alone-in-melanoma-brain/)
- [Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab](https://scholariq.org/papers/anti-pd-1-therapy-in-patients-with-advanced-melanoma-and-preexisting-autoimmune/)
- [Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-versus-ipilimumab-in-resected-stage-iiib-c-and-stage-iv/)
- [Increased stroke risk predicted by compromised cerebral blood flow reactivity](https://scholariq.org/papers/increased-stroke-risk-predicted-by-compromised-cerebral-blood-flow-reactivity/)
- [2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up](https://scholariq.org/papers/2nd-esmo-consensus-conference-on-lung-cancer-early-stage-non-small-cell-lung/)

## University researchers

- [David W. Johnson](https://scholariq.org/researchers/david-w-johnson-2/)
- [Stuart E. R. Bailey](https://scholariq.org/researchers/stuart-e-r-bailey/)

## University top topics

Showing 8 of 25.

- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Renal Transplantation Outcomes and Treatments](https://scholariq.org/topics/renal-transplantation-outcomes-and-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Nonmelanoma Skin Cancer Studies](https://scholariq.org/topics/nonmelanoma-skin-cancer-studies/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.